STAT+: Prime wins Beam arbitration, clearing path to clinic

STAT PlusNewsletterThe Readout Prime wins Beam arbitration, clearing path to clinic AstraZeneca, Ionis report major trial failure, White House pushes for American drug manufacturing, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana KeshavanJuly 9, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. A father fights to create and then save his daughter’s gene therapy, the White House nears a decision on an FDA chief, and the Trump administration pushes drugmakers to reshore generics manufacturing.Advertisement A quest to save Grace — and help rare disease patients everywhere With $70 million and seemingly every fiber of his being, Matt Wilsey built a gene therapy company from scratch — recruiting Nobel laureates and biotech veterans to will an experimental treatment into existence for his daughter Grace. The treatment, for the ultra-rare disorder NGLY1 deficiency, landed her back in the hospital before she slowly began to recover, STAT’s Jason Mast and Matt Herper write. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Adam's Biotech Scorecard July 9, 2026 STAT Plus: 931 days. The drug approval scandal hiding in plain sight Biotech July 9, 2026 STAT Plus: AstraZeneca, Ionis report major trial failure with heart disease drug Advertisement Special Report July 9, 2026 STAT Plus: The quest to save Grace — and clear the way for rare disease patients everywhere Politics July 8, 2026 STAT Plus: RFK Jr. plans to create list of injuries caused by Covid-19 vaccines Health July 8, 2026 Bryan Johnson’s chronic disease is notoriously difficult to diagnose Subscriber Picks